Segall Bryant & Hamill’s ResMed RMD Stock Holding History

Segall Bryant & Hamill’s Portfolio RMD Stock Details RMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,280	Closed	-$268K	–	741
2022 Q2	$268K	Buy	1,280 +410	+47%	+$87.3K	﹤0.01%	676
2022 Q1	$212K	Hold	870	–	–	﹤0.01%	725
2021 Q4	$226K	Hold	870	–	–	﹤0.01%	579
2021 Q3	$229K	Buy	+870	New	+$238K	﹤0.01%	746

Other funds holding RMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

OCBV

Ownership Capital B.V. Amsterdam, Netherlands $178M AUM 4.75% 1-Year Est. Return

Segall Bryant & Hamill's RMD Position: Q3 2022 in Review

Segall Bryant & Hamill sold out of ResMed (RMD) in Q3 2022, closing a stake of 1,280 shares — an estimated $268K sold.

Segall Bryant & Hamill first reported a position in RMD in Q3 2021 and held it in 4 quarters. The position peaked at $268K in Q2 2022. 667 funds tracked by Wall St. Rank hold RMD as of Q3 2022.

Segall Bryant & Hamill reported no remaining ResMed position as of Q3 2022 after selling out during the quarter.
Segall Bryant & Hamill sold 1,280 ResMed shares in Q3 2022, an estimated $268K.
Segall Bryant & Hamill first reported a position in ResMed in Q3 2021 and held it in 4 quarters.
Segall Bryant & Hamill's ResMed position peaked at $268K in Q2 2022.
667 funds tracked by Wall St. Rank held ResMed as of Q3 2022.

Based on Segall Bryant & Hamill's 13F filing for Q3 2022, filed 14 Nov 2022.